A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of Daily CF101 Administered Orally for 12 Weeks to Patients With Osteoarthritis of the Knee
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 05 Feb 2018
At a glance
- Drugs Piclidenoson (Primary)
- Indications Osteoarthritis
- Focus Therapeutic Use
- 30 Jan 2018 Status changed from not yet recruiting to withdrawn prior to enrolment as company has decided not to conduct the study
- 23 Jan 2018 Planned initiation date changed from 1 Nov 2016 to 1 Nov 2018.
- 16 Dec 2015 Planned End Date changed from 1 Dec 2016 to 1 Jan 2019 as reported by ClinicalTrials.gov.